Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.44 |
| ▸ | TK2 | O00142 | 6/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929102 | 1.00 | PYGM (0.50) | PYGMP2RY6TK2P2RY2P2RY4 | |
| SCHEMBL767858 | 0.88 | PYGM (0.49) | PYGMP2RY6TK2P2RY2P2RY4 | |
| SCHEMBL16943081 | 0.88 | PYGM (0.49) | PYGMP2RY6TK2P2RY2P2RY4 | |
| SCHEMBL14928925 | 0.88 | TK2 (0.42) | TK2SMN1; SMN2LMNATHRBHIF1A | |
| SCHEMBL14928930 | 0.88 | TK2 (0.53) | TK2LMNAALDH1A1POLB | |
| SCHEMBL14946210 | 0.88 | TK2 (0.42) | TK2SMN1; SMN2LMNATHRBHIF1A | |
| SCHEMBL14928922 | 0.88 | TK2 (0.53) | TK2LMNAALDH1A1POLB | |
| SCHEMBL18561514 | 0.87 | TK2 (0.40) | PYGMP2RY6TK2SMN1; SMN2LMNA | |
| SCHEMBL14928974 | 0.87 | TK2 (0.40) | PYGMP2RY6TK2SMN1; SMN2LMNA | |
| SCHEMBL18561509 | 0.86 | PYGM (0.51) | PYGMP2RY6TK2P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PYGM 1594/4885P2RY6 339/4885TK2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.